Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × MDS × eprenetapopt × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Recurrence 2 Ovarian Neoplasms 2 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Skin Neoplasms 1 Prostatic Neoplasms 1 Neoplasm Metastasis 1 Myeloid Malignancy 1 Myelodysplastic Syndromes 1 Melanoma 1 MDS 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Leukemia, Myeloid, Acute 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hematologic Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

eprenetapopt 1 Azacitidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03745716 2025-03-18

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

Aprea Therapeutics

Phase 3 Completed

154 enrolled 10 charts

MDS

Data powered by HemOnc (CC BY 4.0) Colophon ⚡